Clinical trials: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Adult B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
This phase I trial studies the side effects and the best dose of deglycosylated ricin A chain-conjugated anti-cluster of differentiation (CD)19/anti-CD22 immunotoxins when given together with cytarabine in treating patients with…
- Trial name
- NCT01408160
- Testing
- Cytarabine, Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma…
- Conditions
- B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)
- Trial name
- NCT07548697
- Testing
- CT1182 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B cell acute lymphoblastic…
- Trial name
- NCT04404660
- Testing
- AUTO1
- Where
- 34 sites in United States, Spain and 1 more
- Volunteers
- 153 people
- Sponsor
- Autolus Limited
Refractory/Recurrent Central Nervous System Lymphoma
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.
- Trial name
- NCT06827782
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
B-cell Acute Lymphoblastic Leukemia
Study Of KITE-753 in R/R B-Cell ALL
The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.
- Trial name
- NCT07674823
- Testing
- KITE-753
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/refractory Diffuse Large B Cell Lymphoma
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Prospective, open-ended, single-arm, multicenter Phase II clinical trial. To evaluate the efficacy of Glofitamab, Poseltinib, and Lenalidomide combination therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
- Trial name
- NCT05335018
- Testing
- Glofitamab, Poseltinib, Lenalidomide
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Seoul National University Hospital
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00962507
- Testing
- everolimus, panobinostat, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00453206
- Testing
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Wake Forest University Health Sciences
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies.
- Trial name
- NCT04684472
- Testing
- Modified anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Liqun Zou
NK Cell, B-cell Lymphoma Recurrent
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsed/refractory non-Hodgkin's B-cell lymphoma. The locations isXiangyang No.1 People's Hospital, Hubei University of Medicine.
- Conditions
- NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
- Trial name
- NCT05909098
- Testing
- autologous NK cell
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Xiangyang No.1 People's Hospital
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT00012298
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan, indium In 111 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
This is a phase 2 study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (ibrutinib), in combination with bendamustine and rituximab (BR) in subjects with previously treated aggressive B cell non Hodgkin lymphoma (aB-NHL)…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma, Recurrent Disease
- Trial name
- NCT02747732
- Testing
- Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
- Where
- 2 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Meirav Kedmi MD
Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
This study aims at evaluating the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B-cell surface antigen CD19…
- Conditions
- Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
- Trial name
- NCT04787263
- Testing
- CD19-CAR_Lenti T cell
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
- Conditions
- Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
- Trial name
- NCT00060684
- Testing
- Pixantrone (BBR 2778), fludarabine, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- CTI BioPharma
Chronic Lymphocytic Leukemia (CLL)
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Investigational Drugs: Ofatumumab (Azerra) + bendamustine (Trenda) Route of Administration: Intravenous (IV) Hypothesis: This study is designed to assess the toxicity and overall response rate.
- Trial name
- NCT01131247
- Testing
- ofatumumab + bendamustine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Nevada Cancer Institute
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
- Trial name
- NCT06601504
- Testing
- HMPL-760 planned dose 1, R-GemOx, HMPL-760 planned dose 2
- Where
- 16 sites in China
- Volunteers
- 61 people
- Sponsor
- Hutchmed
B-ALL, DLBCL
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a…
- Conditions
- B-ALL, DLBCL, B ALL, Dlbcl-Ci
- Trial name
- NCT04512716
- Testing
- 131-I Apamistamab, CAR T-cell
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-cell Lymphoma
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
The purpose of this study is to evaluate the prognostic value of clinical and biological factors in patients with refractory/relapsed Diffuse Large B-Cell Lymphoma.
- Trial name
- PRO-R-IPI (NCT01369784)
- Where
- 56 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
B-cell Non Hodgkin Lymphoma
N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
The purpose of this clinical trial is to learn whether the study drug N-803 is safe and tolerable in patients with B-cell non-Hodgkin lymphoma who have undergone CAR T-cell therapy.
- Trial name
- CARMEN-803 (NCT07049432)
- Testing
- N803
- Where
- United States
- Sponsor
- University of Utah
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
- Trial name
- NCT02384954
- Testing
- Rituximab, N-803
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Altor BioScience
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.